25 February 2018 - A chemotherapy drug called Velcade made Dan Gaffney's death from terminal cancer seem a little further away than before. In contrast to other drugs he had tried without success, it improved a key marker of his multiple myeloma by about 70 per cent.

The deep bone pain that typifies his type of cancer disappeared and, unlike most people, Mr Gaffney, 55, had no side effects after 11 cycles of chemo.

But last November Mr Gaffney's access to the drug under Medicare's Pharmaceutical Benefits Scheme was terminated because it is only approved for 11 treatment cycles.

Read Sydney Morning Herald article